What are the recommended treatment options, including medication choices and dosages, for Clostridioides difficile infection?

Treatment for C. difficile Infection: Medications and Dosages

For initial C. difficile infection, fidaxomicin 200 mg twice daily for 10 days is the preferred first-line treatment, with vancomycin 125 mg four times daily for 10 days as an acceptable alternative. 1

Initial Episode Treatment

The 2021 IDSA/SHEA guidelines establish a clear treatment hierarchy based on disease severity:

Non-Severe to Moderate CDI

• Preferred: Fidaxomicin 200 mg orally twice daily × 10 days 1
• Alternative: Vancomycin 125 mg orally four times daily × 10 days 1
• Last resort (only if above unavailable): Metronidazole 500 mg orally three times daily × 10-14 days 1

Non-severe disease is defined as WBC ≤15,000 cells/μL AND serum creatinine <1.5 mg/dL. Metronidazole should essentially be abandoned as first-line therapy given inferior cure rates and should only be used when fidaxomicin and vancomycin are truly unavailable 2, 3.

Severe CDI

Same dosing as non-severe disease, but fidaxomicin is strongly favored given the higher stakes. Severe disease is indicated by WBC >15,000 cells/μL OR creatinine >1.5× baseline 2.

Fulminant CDI

This is a medical emergency requiring aggressive multi-drug therapy:

• Vancomycin 500 mg orally or via nasogastric tube four times daily 1
• PLUS metronidazole 500 mg IV every 8 hours 1
• If ileus present, ADD rectal vancomycin 500 mg in 100-500 mL normal saline every 6 hours 1, 2

Fulminant disease is defined by hypotension/shock, ileus, or megacolon 1. This requires multidisciplinary management with gastroenterology, infectious disease, and surgery 2.

Recurrent CDI Treatment

First Recurrence (Second Episode)

• Preferred: Fidaxomicin 200 mg twice daily × 10 days, OR fidaxomicin 200 mg twice daily × 5 days then once every other day × 20 days 1
• Alternative: Vancomycin tapered/pulsed regimen: 125 mg four times daily × 10-14 days, then twice daily × 7 days, then once daily × 7 days, then every 2-3 days × 2-8 weeks 1
• Alternative: Standard vancomycin 125 mg four times daily × 10 days (especially if metronidazole was used initially) 1

Second or Subsequent Recurrence (Third+ Episode)

Same options as first recurrence, PLUS:

• Vancomycin 125 mg four times daily × 10 days followed by rifaximin 400 mg three times daily × 20 days 1
• Fecal microbiota transplantation (FMT) - should be offered after the second recurrence 1, 2

The guideline panel recommends trying at least 2 antibiotic recurrences (3 total CDI episodes) before FMT 1, though the 2026 AGA update suggests FMT may be considered earlier in high-risk patients 2.

Adjunctive Therapies

Bezlotoxumab

• Dose: 10 mg/kg IV as single infusion during antibiotic treatment 1
• Use for: Patients at high risk for recurrence (age >65, immunocompromised, severe disease, prior recurrence) 1
• Caution: Contraindicated in congestive heart failure due to FDA safety warning 1
• Limited data when combined with fidaxomicin 1

Suppressive Vancomycin

For patients with multiple recurrences who cannot receive FMT or have failed FMT:

• Vancomycin 125 mg once daily for prolonged secondary prophylaxis 2

Critical Pitfalls to Avoid

1. Do NOT use metronidazole for recurrent CDI - risk of neurotoxicity and hepatotoxicity with repeated courses 4
2. Do NOT use cholestyramine or bile acid binders concurrently with vancomycin or fidaxomicin - they bind and inactivate these antibiotics 2
3. Do NOT perform test of cure - only retest if symptoms persist or worsen 2
4. Do NOT use probiotics for CDI prevention - insufficient evidence 2
5. Do NOT use vancomycin prophylaxis during systemic antibiotic therapy to prevent CDI 2

Why Fidaxomicin is Preferred

Fidaxomicin demonstrates significantly lower recurrence rates (13.3% vs 24.0% with vancomycin) while maintaining equivalent cure rates 5. This narrow-spectrum agent preserves gut microbiota better than vancomycin 2, 6. The 2026 data confirms 50% lower recurrence risk in community-associated CDI 7. However, cost and availability remain practical barriers, making vancomycin an acceptable alternative 1, 2.

The European guidelines similarly favor fidaxomicin and emphasize recurrence risk over severity as the primary treatment determinant 6, aligning with the shift toward preventing the devastating cycle of recurrent disease that significantly impacts mortality and quality of life.